TCRX vs. VYGR, ABSI, FATE, ADPT, NKTX, FUSN, SANA, VIR, NMRA, and FDMT
Should you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Voyager Therapeutics (VYGR), Absci (ABSI), Fate Therapeutics (FATE), Adaptive Biotechnologies (ADPT), Nkarta (NKTX), Fusion Pharmaceuticals (FUSN), Sana Biotechnology (SANA), Vir Biotechnology (VIR), Neumora Therapeutics (NMRA), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "medical" sector.
TScan Therapeutics (NASDAQ:TCRX) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
TScan Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
TScan Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 43.20%. Voyager Therapeutics has a consensus target price of $18.00, indicating a potential upside of 113.78%. Given Voyager Therapeutics' higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than TScan Therapeutics.
Voyager Therapeutics received 355 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 75.00% of users gave TScan Therapeutics an outperform vote while only 67.32% of users gave Voyager Therapeutics an outperform vote.
Voyager Therapeutics has higher revenue and earnings than TScan Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, TScan Therapeutics and TScan Therapeutics both had 2 articles in the media. TScan Therapeutics' average media sentiment score of 0.30 beat Voyager Therapeutics' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the media.
Voyager Therapeutics has a net margin of -2.56% compared to TScan Therapeutics' net margin of -653.50%. Voyager Therapeutics' return on equity of -1.28% beat TScan Therapeutics' return on equity.
82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 2.8% of TScan Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Voyager Therapeutics beats TScan Therapeutics on 10 of the 16 factors compared between the two stocks.
Get TScan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TScan Therapeutics Competitors List
Related Companies and Tools
